Zobrazeno 1 - 10
of 467
pro vyhledávání: '"Tobias, Heintges"'
Autor:
Felix O. Hofmann, Volker Heinemann, Melvin D’Anastasi, Alena B. Gesenhues, Nina Hesse, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Markus Moehler, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Dominik P. Modest, Sebastian Stintzing, Julian W. Holch
Publikováno v:
European Radiology. 33:1174-1184
Objectives: Early tumor shrinkage (ETS) quantifies the objective response at the first assessment during systemic treatment. In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for patient survival. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::480fbb567e92aa156142573c62e61d6b
https://doi.org/10.1007/s00330-022-09053-2
https://doi.org/10.1007/s00330-022-09053-2
Autor:
Laura E. Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Dominik P. Modest, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Clemens Giessen-Jung, Jens Uhlig, Bettina Peuser, Claudio Denzlinger, Arndt Stahler, Lena Weiss, Kathrin Heinrich, Swantje Held, Andreas Jung, Thomas Kirchner, Volker Heinemann
Publikováno v:
British Journal of Cancer. 127:836-843
Summary Background The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy of FOLFIRI plus either cetuximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a68edabca01df58b33a3611c4acafc2
https://doi.org/10.1038/s41416-022-01854-y
https://doi.org/10.1038/s41416-022-01854-y
Autor:
Arndt Stahler, Sebastian Stintzing, Jobst C. von Einem, Christoph B. Westphalen (Benedikt), Kathrin Heinrich, Nicole Krämer, Marlies Michl, Dominik P. Modest, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Markus Moehler, Florian Kaiser, Thomas Kirchner, Andreas Jung, Volker Heinemann
Publikováno v:
European Journal of Cancer. 169:223-225
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591767f775fe1d622a7ae12980cc66ff
https://doi.org/10.1016/j.ejca.2022.04.003
https://doi.org/10.1016/j.ejca.2022.04.003
Autor:
Tobias Heintges, J. C. von Einem, Swantje Held, Christoph Kahl, Florian Kaiser, Marlies Michl, Alexander Kiani, Werner Scheithauer, L. Fischer von Weikersthal, Markus Moehler, Volker Heinemann, Frank Kullmann, Thomas Decker, Julian Walter Holch, Sebastian Stintzing
Publikováno v:
Annals of Oncology. 31:72-78
Background Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for targeted therapy, we investigated its prognostic impact with early tumor shrinkage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::079e82de852bda7021bd410425d991ca
https://doi.org/10.1016/j.annonc.2019.10.001
https://doi.org/10.1016/j.annonc.2019.10.001
Autor:
Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann, T. Kirchner, Alexander Kiani, Andreas Jung, Dan Aderka, Thomas Decker, Frank Kullmann, L. Fischer von Weikersthal, Werner Scheithauer, Pratyaksha Wirapati, Tobias Heintges, Christian A. Lerchenmuller, H. J. Lenz, Daniel Neureiter, Markus Moehler, G. Seipelt, Sabine Tejpar, Christoph Kahl, S-E. Al-Batran, Swantje Held, Florian Kaiser
Publikováno v:
Annals of Oncology
BACKGROUND: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e67e4161f5dd2f0619cf24b4869e33a
https://doi.org/10.1093/annonc/mdz387
https://doi.org/10.1093/annonc/mdz387
Autor:
Lian, Liu, Nicole Tonya, Erickson, Ingrid, Ricard, Ludwig Fischer, von Weikersthal, Markus M, Lerch, Thomas, Decker, Alexander, Kiani, Florian, Kaiser, Tobias, Heintges, Christoph, Kahl, Frank, Kullmann, Werner, Scheithauer, Hartmut, Link, Heinz-Gert, Höffkes, Markus, Moehler, Alena Britta, Gesenhues, Sebastian, Theurich, Marlies, Michl, Dominik P, Modest, Hana, Algül, Sebastian, Stintzing, Volker, Heinemann, Julian W, Holch
Publikováno v:
International journal of cancerREFERENCES. 150(1)
Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies. This retrospective analysis of the FIRE-3 study evaluated the evolution of body weight in patients with metastatic colorectal cancer (mCRC). FIRE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c08c48d5763f4db9a54cc5855c4a5cf
https://pubmed.ncbi.nlm.nih.gov/35353388
https://pubmed.ncbi.nlm.nih.gov/35353388
Autor:
Sebastian Stintzing, Jobst C. von Einem, Thomas Kirchner, Marlies Michl, Alexander Kiani, Tobias Heintges, Dominik Paul Modest, Markus Moehler, Ludwig Fischer von Weikersthal, Volker Heinemann, Christoph B. Westphalen, Christoph Kahl, Arndt Stahler, Kathrin Heinrich, Thomas Decker, Frank Kullmann, Nicole C. Krämer, Werner Scheithauer, Andreas Jung, Florian Kaiser
Publikováno v:
European journal of cancer (Oxford, England : 1990). 137
Background Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a90609cd34b450d8e8abe03d71e3ae07
https://pubmed.ncbi.nlm.nih.gov/35570084
https://pubmed.ncbi.nlm.nih.gov/35570084
Autor:
Markus Moehler, Frank Kullmann, Jobst C. von Einem, Salah-Eddin Al-Batran, Sebastian Müller, Lisa Miller-Phillips, Thomas Kirchner, Julian Walter Holch, Volker Heinemann, Andreas Jung, Thomas Decker, Hartmut Link, Andreas Rost, Michael Scholz, Alexander Kiani, Werner Scheithauer, Tobias Heintges, Christian A. Lerchenmuller, Dominik Paul Modest, Heinz-Gert Höffkes, Ursula Vehling-Kaiser, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Ingrid Ricard, Reinhard Udo Lindig, Christoph Kahl
Publikováno v:
International Journal of Cancer. 142:1047-1055
In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of initially unresectable LL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29874f96142ae356a9977d9860ef22a0
https://doi.org/10.1002/ijc.31114
https://doi.org/10.1002/ijc.31114
Autor:
Andreas Jung, Markus Moehler, Werner Scheithauer, Tobias Heintges, Jobst C. von Einem, Martina Stauch, Christoph Kahl, Frank Kullmann, Swantje Held, Alexander Kiani, Thomas Kirchner, Salah-Eddin Al-Batran, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Fire study investigators, Sebastian Stintzing, Ursula Vehling-Kaiser, Dominik Paul Modest, Christian A. Lerchenmuller, G. Seipelt
Publikováno v:
International Journal of Cancer. 140:1918-1925
We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773257054f983763ffa9fe57f120c5df
https://doi.org/10.1002/ijc.30592
https://doi.org/10.1002/ijc.30592
Autor:
Christoph Kahl, Sebastian Stintzing, Werner Scheithauer, Salah-Edin Al-Batran, Christoph Lerchenmüller, Dominik Paul Modest, Andreas Jung, Volker Heinemann, Thomas Kirchner, Ludwig Fischer von Weikersthal, Thomas Decker, Markus Moehler, Lisa Miller-Phillips, Tobias Heintges, G. Seipelt, Alexander Kiani, Frank Kullmann, Swantje Held, Florian Kaiser
Publikováno v:
British Journal of Cancer
Background Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival. This analysis ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e1f3c0ca76a04fa9a3cf26d1f70c02
